In recent years, immune checkpoint inhibitor (ICI) targeting programmed death-1 (PD-1) and PD-1 ligand (PD-L1) has revolutionized cancer treatment by harnessing the power of the immune system, and these ICIs dramatically improve the clinical outcomes of advanced NSCLC patients without driver mutations (9–12). Here, CD274 is linked to non-small cell lung carcinoma.